9 million Magpies! More than 20 billion oral anti-sugar drug market blasted

Table 1: Main content of drug registration approval(source: company announcement)Figure 1: Annual sales trend of end chemical drugs oral diabetes in China's public medical institutions (unit: million yuan)(source: Minet China public medical institutions terminal competition pattern)Figure 2: Annual sales of end chemical drugs agretin in China's public medical institutions Trends (units: 10,000 yuan)(source: Minet.com China's public medical institutions terminal competition pattern)meternet data show that in 2018 in China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal chemical drug oral diabetes market size has reached 25.6 billion yuanit is reported that benzoic acid agregintableta is mainly used to treat type 2 diabetes, first developed by Japan's Takeda Pharmaceutical Industry Co., Ltd., listed in Japan in 2010, minet multinational listed companies sales database data show that in 2017 the global sales of the product is 53.7 billion yen (about 500 million U.Sdollars)in 2013, the original research products in China was approved for import listing, the commodity name "Nishina", in 2018 in China's public medical institutions terminal sales reached 62.85 million yuan, a growth rate of 187.68 percent, the product for the 2019 version of the national health insurance catalog B products, products into the domestic will usher in market volumeYabao Pharmaceuticals said in a statement that the company's first submission of benzoic acid agretin tablet registration application processing time is February 22, 2017, there is no other company other than the company to obtain the registration approval of benzoic acid agritide tabletsUp to now, the company has invested in research and development projects of the product about 8.89 million yuanmeter net MED China Drug Review Database 2.0 data show that as of November 29, 2019, benzoic acid agretin tablets in the trial of the imitation listing application enterprises are also Shenzhen Seaside Pharmaceuticals, Stone Pharmaceutical Sio-Yi Pharmaceuticals, Hunan Qianjin Xiangjiang Pharmaceuticals, National Pharmaceutical Group Guorui Pharmaceuticals, Guangdong Dongsun Pharmaceuticals, Jiangsu Notai OSano Biopharmaceuticals, Jiangsu Zhongtian Pharmaceuticals, Jiangsu Deyuan Pharmaceuticals, the registration of 4 genericcategorysources: Internet database, announcement of listed companies